Status:
COMPLETED
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
Lead Sponsor:
Osaka University
Collaborating Sponsors:
Human Genome Center, Institute of Medical Science, University of Tokyo
Conditions:
Neovascular Maculopathy
Age Related Macular Degeneration
Eligibility:
All Genders
40-85 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and time to progression of HLA-A\*2402 or A\*0201 restricted epitope peptides VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in patients with Ne...
Detailed Description
VEGF receptor 1 and 2 are essential targets to pathogenic angiogenesis, and we identified that peptides derived from these receptors significantly induce the effective tumor specific CTL response in v...
Eligibility Criteria
Inclusion
- Neovascular Maculopathy including Age Related Macular Degeneration.
- Resistant against PDT or Anti VEGF therapy or Patient disagree with these therapies.
- with HLA-A\*2402 or A\*0201
Exclusion
- Pregnancy(woman of childbearing potential:Refusal or inability to use effective means of contraception) Breastfeeding Active or uncontrolled infection Unhealed external wound Concurrent treatment with steroids or immunosuppressing agent Uncontrolled brain and/or intraspinal lesion(s) Decision of unsuitableness by principal investigator or physician-in-charge
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00791570
Start Date
October 1 2008
End Date
April 1 2012
Last Update
October 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ophthalmology, Osaka University Medical School
Suita, Osaka, Japan, 565